Rob Dillard

DocwireNews

Researchers of a study published in JAMA Dermatology characterized persistent radiation-induced <a href="https://www.docwirenews.com/conference-coverage/san-antonio_breast_cancer_symposium_2019/reducing-chemotherapy-induced-alopecia/">alopecia</a> (pRIA) in patients with primary central nervous system tumors (CNS) or head and neck sarcomas and provided treatment options.
In this retrospective cohort study, researchers evaluated 71 children and adults diagnosed with primary CNS tumors or head and neck sarcomas for pRIA at two large tertiary care hospitals and comprehensive care cancer centers between January 2011 and January 30, 2019. The primary outcomes were defined as the clinical and trichoscopic features, scalp radiation dose-response relationship, and response to topical minoxidil were assessed using standardized clinical photographs of the scalp, trichoscopic images, and radiotherapy treatment plans.
According to the results, the average estimated scalp radiation dose was 39.6 (15.1-50.0) Gy; higher dose (OR= 1.15; 95% CI, 1.04 to 1.28) and proton irradiation (OR=5.7; 95% CI, 1.05 to 30.8) which was linked with with greater alopecia severity (P &lt; .001), the researchers noted. They observed that the dose at which 50% of patients were estimated to have severe (grade 2) alopecia was 36.1 Gy (95% CI, 33.7 to 39.6 Gy).
The researchers wrote that of the characteristics, “Predominant trichoscopic features included white patches (16 of 28 [57%]); in 15 patients, hair-shaft caliber negatively correlated with scalp dose (correlation coefficient, −0.624; P = .01). The association between hair density and scalp radiation dose was not statistically significant (−0.381; P = .16). Twenty-eight of 34 patients (82%) responded to topical minoxidil, 5% (median follow-up, 61 [interquartile range, 21-105] weeks); 4 of 25 (16%) topical minoxidil recipients with clinical images improved in severity grade. Two patients responded to hair transplantation and 1 patient responded to plastic surgical reconstruction.”
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Topical <a href="https://twitter.com/hashtag/minoxidil?src=hash&amp;ref_src=twsrc%5Etfw">#minoxidil</a> may improve <a href="https://twitter.com/hashtag/alopecia?src=hash&amp;ref_src=twsrc%5Etfw">#alopecia</a> observed in persistent radiation-induced alopecia, and surgical procedures may be effective in nonresponders <a href="https://t.co/KfErMAQsYM">https://t.co/KfErMAQsYM</a> ONC, SUR
— JAMA Dermatology (@JAMADerm) <a href="https://twitter.com/JAMADerm/status/1291041293766983680?ref_src=twsrc%5Etfw">August 5, 2020</a>
</blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
 
“Persistent radiation-induced alopecia among patients with primary CNS tumors or head and neck sarcomas represents a dose-dependent phenomenon that has distinctive clinical and trichoscopic features,” the researchers authors concluded. “The findings of this study suggest that topical minoxidil and procedural interventions may have benefit in the treatment of pRIA.”

Researchers of a study published in JAMA Dermatology characterized persistent radiation-induced <a href="https://www.docwirenews.com/conference-coverage/san-antonio_breast_cancer_symposium_2019/reducing-chemotherapy-induced-alopecia/">alopecia</a> (pRIA) in patients with primary central nervous system tumors (CNS) or head and neck sarcomas and provided treatment options.In this retrospective cohort study, researchers evaluated 71 children and adults diagnosed with primary CNS tumors or head and neck sarcomas for pRIA at two large tertiary care hospitals and comprehensive care cancer centers between January 2011 and January 30, 2019. The primary outcomes were defined as the clinical and trichoscopic features, scalp radiation dose-response relationship, and response to topical minoxidil were assessed using standardized clinical photographs of the scalp, trichoscopic images, and radiotherapy treatment plans.According to the results, the average estimated scalp radiation dose was 39.6 (15.1-50.0) Gy; higher dose (OR= 1.15; 95% CI, 1.04 to 1.28) and proton irradiation (OR=5.7; 95% CI, 1.05 to 30.8) which was linked with with greater alopecia severity (P &lt; .001), the researchers noted. They observed that the dose at which 50% of patients were estimated to have severe (grade 2) alopecia was 36.1 Gy (95% CI, 33.7 to 39.6 Gy).The researchers wrote that of the characteristics, “Predominant trichoscopic features included white patches (16 of 28 [57%]); in 15 patients, hair-shaft caliber negatively correlated with scalp dose (correlation coefficient, −0.624; P = .01). The association between hair density and scalp radiation dose was not statistically significant (−0.381; P = .16). Twenty-eight of 34 patients (82%) responded to topical minoxidil, 5% (median follow-up, 61 [interquartile range, 21-105] weeks); 4 of 25 (16%) topical minoxidil recipients with clinical images improved in severity grade. Two patients responded to hair transplantation and 1 patient responded to plastic surgical reconstruction.”<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Topical <a href="https://twitter.com/hashtag/minoxidil?src=hash&amp;ref_src=twsrc%5Etfw">#minoxidil</a> may improve <a href="https://twitter.com/hashtag/alopecia?src=hash&amp;ref_src=twsrc%5Etfw">#alopecia</a> observed in persistent radiation-induced alopecia, and surgical procedures may be effective in nonresponders <a href="https://t.co/KfErMAQsYM">https://t.co/KfErMAQsYM</a> ONC, SUR
— JAMA Dermatology (@JAMADerm) <a href="https://twitter.com/JAMADerm/status/1291041293766983680?ref_src=twsrc%5Etfw">August 5, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script> “Persistent radiation-induced alopecia among patients with primary CNS tumors or head and neck sarcomas represents a dose-dependent phenomenon that has distinctive clinical and trichoscopic features,” the researchers authors concluded. “The findings of this study suggest that topical minoxidil and procedural interventions may have benefit in the treatment of pRIA.”

Damiana Chiavolini, PhD

Piperacillin May Be a Promising Targeted Therapy for Lyme Disease

Infectious Disease

David M. Waterhouse, MD, MPH

Bringing Clinical Trials to Patients: A Vision for Accessible Cancer Research

Breast Cancer News

Marina De Brot, MD, PhD

New AI Tool Boosts Accuracy in HER2-Low and HER2-Ultralow Breast Cancer Scoring

HER2 Breast Cancer

Latest News

Study: Characteristics, Treatment of Radiation-Induced Alopecia in Patients with Certain Cancers

Head and Neck Cancer

Researchers of a study published in JAMA Dermatology characterized persistent radiation-induced alopecia (pRIA) in patients with primary central nervous system tumors (CNS) or ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Diabetes

Obesity

Metabolic Care Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe